Clinical Trial Update: Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 study of ivacaftor in cystic fibrosis patients aged 12 and older homozygous for the F508del-CFTR mutation was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (Kalydeco) (ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2012-08-21